FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213302345> ?p ?o ?g. }

• W4213302345 abstract "Abstract Metastatic breast cancer (mBC) patients have a high risk of progression and face poor prognosis overall, with about one third (34%) surviving five years or more. In rare instances (2–4% of cases) patients with mBC have ERBB2 (HER2) activating mutations but are ERBB2 non-amplified. Neratinib is a potent, irreversible inhibitor that binds HER2 and inhibits downstream signaling. We used the previously validated high-definition single cell assay (HDSCA) workflow to investigate the clinical significance of the liquid biopsy in ERBB2 mutant, non-amplified, post-menopausal mBC patients starting neratinib and fulvestrant combination therapy. Characterization with a comprehensive liquid biopsy methodology (HDSCA) included genomic analysis of both the cell-free DNA (cfDNA) and single circulating tumor cells (CTCs) to monitor tumor evolution and identify potential mutational variants unique to the patient’s clinical response. A limited series of five sequentially enrolled patients presented here were from the MutHER ( https://www.clinicaltrials.gov , NCT01670877) or SUMMIT ( https://www.clinicaltrials.gov , NCT01953926) trials. Patients had an average of 5.4 lines of therapy before enrollment, variable hormone receptor status, and ERBB2 mutations at diagnosis and during treatment. CTC enumeration alone was not sufficient to predict clinical response. Treatment pressure was shown to lead to an observable change in CTC morphology and genomic instability (GI), suggesting these parameters may inform prognosis. Single cell copy number alteration (CNA) analysis indicated that the persistence or development of a clonal population of CTCs during treatment was associated with a worse response. Hierarchical clustering analysis of the single cells across all patients and timepoints identified distinct aberrant regions shared among patients, comprised of 26 genes that are similarly affected and may be related to drug resistance. Additionally, the genomic analysis of the cfDNA, identified new mutations in ERBB2 , PIK3CA , and TP53 that arose likely due to treatment pressure in a patient with poor response, further providing insights on the dynamics of the cancer genome over the course of therapy. The data presented in this small cohort study demonstrates the feasibility of real-time molecular profiling of the cellular and acellular fractions of the liquid biopsy using the HDSCA methodology. Additional studies are necessary to determine the potential use of morphometric and genomic analysis as a prognostic tool to advance personalized oncology." @default.
• W4213302345 created "2022-02-24" @default.
• W4213302345 creator A5000472988 @default.
• W4213302345 creator A5002226640 @default.
• W4213302345 creator A5007782183 @default.
• W4213302345 creator A5025053302 @default.
• W4213302345 creator A5026918069 @default.
• W4213302345 creator A5032612608 @default.
• W4213302345 creator A5038921783 @default.
• W4213302345 creator A5039465161 @default.
• W4213302345 creator A5043781144 @default.
• W4213302345 creator A5055664434 @default.
• W4213302345 creator A5073079380 @default.
• W4213302345 creator A5090150532 @default.
• W4213302345 date "2022-02-18" @default.
• W4213302345 modified "2023-10-13" @default.
• W4213302345 title "Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib" @default.
• W4213302345 cites W1494447899 @default.
• W4213302345 cites W1506365371 @default.
• W4213302345 cites W1559641548 @default.
• W4213302345 cites W1790243993 @default.
• W4213302345 cites W1988106817 @default.
• W4213302345 cites W2003069503 @default.
• W4213302345 cites W2032518018 @default.
• W4213302345 cites W2038081635 @default.
• W4213302345 cites W2053059159 @default.
• W4213302345 cites W2062109911 @default.
• W4213302345 cites W2063824048 @default.
• W4213302345 cites W2068674866 @default.
• W4213302345 cites W2069707480 @default.
• W4213302345 cites W2070059866 @default.
• W4213302345 cites W2070139504 @default.
• W4213302345 cites W2087527158 @default.
• W4213302345 cites W2095156669 @default.
• W4213302345 cites W2095659509 @default.
• W4213302345 cites W2104457974 @default.
• W4213302345 cites W2114195503 @default.
• W4213302345 cites W2115759102 @default.
• W4213302345 cites W2126903025 @default.
• W4213302345 cites W2127457632 @default.
• W4213302345 cites W2128571346 @default.
• W4213302345 cites W2141393790 @default.
• W4213302345 cites W2149952977 @default.
• W4213302345 cites W2151264766 @default.
• W4213302345 cites W2153565541 @default.
• W4213302345 cites W2154246971 @default.
• W4213302345 cites W2156385497 @default.
• W4213302345 cites W2156858440 @default.
• W4213302345 cites W2158927987 @default.
• W4213302345 cites W2195054423 @default.
• W4213302345 cites W2318605753 @default.
• W4213302345 cites W2396384645 @default.
• W4213302345 cites W2415340135 @default.
• W4213302345 cites W2419426348 @default.
• W4213302345 cites W2515856687 @default.
• W4213302345 cites W2584922809 @default.
• W4213302345 cites W2587081752 @default.
• W4213302345 cites W2592465655 @default.
• W4213302345 cites W2613784923 @default.
• W4213302345 cites W2616354594 @default.
• W4213302345 cites W2726739357 @default.
• W4213302345 cites W2765435739 @default.
• W4213302345 cites W2770409203 @default.
• W4213302345 cites W2770503852 @default.
• W4213302345 cites W2783528963 @default.
• W4213302345 cites W2785610956 @default.
• W4213302345 cites W2811305164 @default.
• W4213302345 cites W2887239012 @default.
• W4213302345 cites W2895955393 @default.
• W4213302345 cites W2896932075 @default.
• W4213302345 cites W2910011825 @default.
• W4213302345 cites W2912329425 @default.
• W4213302345 cites W2921497169 @default.
• W4213302345 cites W2955911683 @default.
• W4213302345 cites W2961375208 @default.
• W4213302345 cites W3001195005 @default.
• W4213302345 cites W3099860312 @default.
• W4213302345 cites W3111625812 @default.
• W4213302345 cites W4234746319 @default.
• W4213302345 cites W4239989216 @default.
• W4213302345 cites W4303066689 @default.
• W4213302345 cites W4376848401 @default.
• W4213302345 doi "https://doi.org/10.1038/s41523-022-00390-5" @default.
• W4213302345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35181666" @default.
• W4213302345 hasPublicationYear "2022" @default.
• W4213302345 type Work @default.
• W4213302345 citedByCount "7" @default.
• W4213302345 countsByYear W42133023452022 @default.
• W4213302345 countsByYear W42133023452023 @default.
• W4213302345 crossrefType "journal-article" @default.
• W4213302345 hasAuthorship W4213302345A5000472988 @default.
• W4213302345 hasAuthorship W4213302345A5002226640 @default.
• W4213302345 hasAuthorship W4213302345A5007782183 @default.
• W4213302345 hasAuthorship W4213302345A5025053302 @default.
• W4213302345 hasAuthorship W4213302345A5026918069 @default.
• W4213302345 hasAuthorship W4213302345A5032612608 @default.
• W4213302345 hasAuthorship W4213302345A5038921783 @default.
• W4213302345 hasAuthorship W4213302345A5039465161 @default.
• W4213302345 hasAuthorship W4213302345A5043781144 @default.
• W4213302345 hasAuthorship W4213302345A5055664434 @default.

• next